Completed PHASE1 INTERVENTIONAL 3-arm NCT01988311

Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

Sponsor: Johns Hopkins University

Conditions Central Nervous System Agents Hallucinogens Pharmacologic Actions Psilocybin Psychotropic Drugs Therapeutic Uses

Interventions psilocybin

Updated 6 times since 2017 Last updated: May 19, 2014 Started: May 31, 2013 Primary completion: Jan 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Central Nervous System Agents and Hallucinogens, this trial is completed. The trial is conducted by Johns Hopkins University and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Johns Hopkins University

Data source: Johns Hopkins University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States